evipedia.ai
← Back

Double Filtration Plasmapheresis for Health & Longevity

Created on 10/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Double filtration plasmapheresis, a long-used hospital blood-filtering procedure for blood-fat and antibody-driven diseases now offered to healthy adults, removes very large molecules from the blood's liquid part. Its firmest effect is a large but short-lived drop in cholesterol-carrying particles. Claims of slower aging and chemical removal rest on studies without comparison groups or on related procedures. It is costly and short-acting, with little evidence of long-term benefit in healthy people. (Full Review)

Protocol

Treated plasma volume (dose)
0.75–1.5 plasma volumes
Sources differ; about 3 L in lipid filtration
Single session versus series
Series for sustained lowering
Single sessions give only a transient change; lipid programs run weekly
Healthy-adult single sessions
One session, then laboratory testing
Repeat intervals are set by clinics, not by trials
Time to effect
LDL cholesterol
Within hours
Laboratory changes after one session; levels drift back between sessions
Hearing recovery
10 days
Recovery measured at day 10 after two sessions
Cardiovascular events
Years
Clinical outcomes in trials needed years

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Hemoglobin below 8 g/dL, or body weight under 40 kg
  • Platelet count below 100,000/mm³ or known bleeding risk
  • Blood-clotting disorders or significantly impaired coagulation
  • Active infection, inflammation or fever
  • Recent myocardial infarction, hypertensive crisis, or serious kidney or liver impairment
  • People who must continue ACE inhibitors and cannot pause them
    •
Key Interactions
  • ACE inhibitors (enalapril): Caution; commonly paused before sessions
  • Anticoagulants (warfarin) and antiplatelet drugs (clopidogrel): Caution (theoretical)
  • Statins (atorvastatin): Monitor
  • Antibody-based drugs (basiliximab) and IVIG: Monitor
  • Small-molecule chemotherapy (cisplatin): No interaction found
  • Liposomal and nanoparticle drugs (pegylated liposomal doxorubicin): Monitor
  • Blood-pressure-lowering drugs (amlodipine): Caution (theoretical)
  • Over-the-counter pain relievers (aspirin): Caution (theoretical)
  • Supplements with bleeding effects (fish oil): Caution (theoretical)
  • Iron and vitamin B12 supplements: Monitor
  • Additive lipid-lowering supplements (red yeast rice): Monitor (theoretical)
  • Other interventions (plasma or blood donation, vaccination): Caution (theoretical)
    •

Risk & Side Effects

  • High:
  • Medium: Clotting factor depletion and bleeding; allergic and anaphylactoid reactions
    •
  • Low: Hypotension and vasovagal reactions; hemolysis; vascular access complications and bloodstream infection; iron, ferritin and vitamin B12 depletion; immunoglobulin depletion; citrate-related low blood calcium; heparin-induced thrombocytopenia and thrombosis
    •
  • Speculative: Epigenetic age acceleration; loss of HDL and protective plasma proteins; rebound redistribution of mobilized pollutants
    •

Monitoring

Marker Target Why
Fibrinogen 200–400 mg/dL Safety check: low levels stop or space sessions
Hemoglobin 12.0–15.5 g/dL women, 13.5–17.5 g/dL men Safety check: low values defer sessions
Platelets 150,000–450,000/mm³ Safety check: low values defer sessions
LDL cholesterol Below 55 mg/dL for very-high cardiovascular risk Marker DFPP is expected to change
Lipoprotein(a) Below 30 mg/dL Marker DFPP is expected to change
HDL cholesterol Above 40 mg/dL men, above 50 mg/dL women Marker DFPP is expected to change
IgG 700–1,600 mg/dL Safety check: low values defer sessions
Ferritin 24–336 ng/mL men, 11–307 ng/mL women Safety check: low values prompt repletion
Vitamin B12 200–900 pg/mL Safety check: low values prompt repletion
hs-CRP Below 1.0 mg/L, low-risk category Marker DFPP is expected to change
PFAS panel (PFOS, PFOA) No established target; track change from own baseline Marker DFPP is expected to change; detects rebound
Blood pressure and pulse Not specified in the ER Safety check throughout each session
Coagulation tests Not specified in the ER Baseline safety and reference for change
Kidney and liver function Not specified in the ER Baseline safety and reference for change

Cadence: Blood pressure and pulse throughout each session; fibrinogen, hemoglobin and platelets before every session in a series; lipids, Lp(a) and hs-CRP 1 day and 2 weeks after the first session, then before each later course; ferritin, vitamin B12 and IgG every 3 months during repeated courses; pollutant panels 4 weeks after a course

Qualitative Assessment

  • Energy and fatigue levels in the days after sessions
  • Light-headedness, fainting or palpitations during and after sessions
  • Bruising or bleeding at puncture sites and elsewhere
  • Frequency of infections in the weeks after a course
  • Exercise tolerance and recovery
  • Vision or hearing changes when those are the treatment goal
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.